Competition in the weight-loss drug market has reached a fever pitch, with pharmaceutical giants Novo Nordisk and Eli Lilly locked in a high-stakes battle for dominance. The latest round, however, saw Novo Nordisk stumble as its much-anticipated next-generation obesity treatment, CagriSema, failed to outperform Eli Lilly’s Zepbound (tirzepatide) in a pivotal clinical trial. The results, announced on February 24, 2026, sent shockwaves through the industry and the stock market, raising questions about Novo’s future in an increasingly competitive landscape.
The phase 3 open-label study, as reported by Reuters and Fierce Biotech, enrolled 809 adults with obesity and compared the efficacy of Novo Nordisk’s CagriSema—a weekly injection combining 2.4 mg of cagrilintide and 2.4 mg of semaglutide—against a 15 mg weekly dose of Eli Lilly’s tirzepatide, marketed as Zepbound for weight loss in the U.S. and Mounjaro in Europe. After 84 weeks, patients on CagriSema achieved an average weight loss of 23%, while those on tirzepatide lost 25.5% of their body weight. At first glance, the 2.5 percentage point difference might seem minor, but for investors and industry analysts, it was a significant blow to Novo’s ambitions.
“This is a worst-case scenario for Novo, now it is clinically proven that Mounjaro is better than CagriSema,” Markus Manns of Union Investment, a shareholder in both Novo and Lilly, told Reuters. “The base case was that Mounjaro and CagriSema are similar... Upside was superiority, but nobody had on the agenda, that Cagri would be worse than Mounjaro.”
The market’s response was swift and dramatic. Novo Nordisk’s shares plummeted 15% to levels not seen since 2021, wiping out over $400 billion from its market capitalization since its 2024 peak. That drop effectively erased the gains Novo enjoyed after the successful launch of Wegovy, its earlier weight-loss blockbuster, in 2021. In contrast, Eli Lilly’s shares rose 3.5%, reflecting growing investor confidence in Zepbound’s continued market momentum.
Per Hansen, an analyst at Nordnet, put it succinctly: “Weight loss of 23% versus 25.5% after 84 weeks may seem like a minor difference, but to investors it’s very significant. In a winner-takes-all world Eli Lilly has cemented its strong momentum.”
The clinical trial was designed with the intention of demonstrating that CagriSema would be at least as effective as tirzepatide in helping patients lose weight. Novo had positioned CagriSema as a more potent successor to Wegovy, especially as the latter faces patent expiration after 2030. The hope was that CagriSema could be a powerful contender against Zepbound and help Novo Nordisk regain its leadership in the obesity drug market.
Yet, the outcome was not what Novo had envisioned. Chief Scientific Officer Martin Holst Lange acknowledged the disappointment in a call with journalists, noting, “CagriSema had performed in line with previous trials. But, surprisingly, Zepbound had performed unusually well on efficacy compared to what has been typically seen in most previous trials of similar nature.” In a statement, Holst Lange tried to maintain an optimistic outlook, saying, “CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone.”
Still, analysts remained skeptical. Michael Leuchten at Jefferies wrote, “Without the level of superiority over current high-volume GLP-1s, we believe it is difficult to command a premium positioning for the drug.” Henrik Hallengreen Laustsen, an analyst at Jyske Bank, described the news as a “fairly big setback” for Novo, pointing out that, according to consensus estimates, 60% of Novo’s future growth was expected to come from CagriSema.
The pressure is now on Novo Nordisk to chart a new course. The company announced plans to launch a high-dose trial for CagriSema in the second half of 2026, hoping that a more potent formulation could close the efficacy gap. In addition, Novo has already submitted an application to the U.S. Food and Drug Administration (FDA) for approval of CagriSema for weight loss, with a potential market launch next year. Other ongoing trials in the Redefine program include a phase 3 study comparing CagriSema to placebo, expected to report results in the first half of 2027.
Novo’s challenges extend beyond clinical performance. In 2025, the company laid off 9,000 employees and appointed a new CEO, Maziar Mike Doustdar, in an effort to refocus after disappointing U.S. sales of Wegovy. Doustdar had previously told journalists that Novo’s “base expectation” was to show noninferiority to tirzepatide, with “the outside case” being superiority. Ultimately, CagriSema achieved neither, raising doubts about a key pillar of Novo’s next-generation obesity strategy.
Meanwhile, Eli Lilly is capitalizing on its success. On February 23, 2026, the company announced FDA approval to launch a four-dose KwikPen for Zepbound, allowing patients to receive a full month of treatment with a single device. This innovation could further strengthen Zepbound’s position in the market, especially as Novo’s Wegovy has been available as a single-dose weekly autoinjector pen in the U.S. since 2021.
The implications of these developments are far-reaching. The weight-loss drug market has exploded in recent years, driven by rising obesity rates and the promise of highly effective medications. Both Novo Nordisk and Eli Lilly have raced to develop new therapies that offer greater weight loss, better tolerability, and more convenient delivery methods. Yet, as the latest results show, even a small edge in efficacy can have outsized consequences for market share and investor sentiment.
Looking ahead, Novo Nordisk is betting on innovation to regain its footing. In addition to the high-dose CagriSema trial, the company is advancing other weight-loss candidates, including cagrilintide as a standalone therapy and zenagamtide, a dual GLP-1 and amylin agonist set to enter late-stage study in 2026. There’s also UBT251, a triple agonist for GLP-1, GIP, and glucagon, now in early clinical trials. Whether these efforts will be enough to restore Novo’s leadership remains to be seen.
For now, Eli Lilly enjoys a clear advantage, with Zepbound’s superior results and new device approvals reinforcing its momentum. Novo Nordisk, once the undisputed leader, faces an uphill battle—not just to match its rival’s efficacy, but to convince investors and patients that it still has what it takes to transform obesity care.
The race for obesity drug supremacy is far from over, but this round has left Novo Nordisk searching for answers as Eli Lilly surges ahead.